Arrangements made between manufacturers and payers which are being implemented for innovative treatm...
Read moreGiven the shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust...
Read more"Payer" generally refers to people or bodies other than the patient that finance or refund the cost ...
Read moreDifferences in market access and reimbursement processes are an important factor in determining the ...
Read moreThis resolution includes proposed reforms to the market access (including pricing) landscape designe...
Read more"Market Access" describes activities and processes that pharmaceutical and biotech companies underta...
Read morePrescription drug prices in the US rank among the highest in the world and the US spent $1220 on ph...
Read moreThe Westminster Health Forum organise senior level conferences on public policy relating to health a...
Read moreWith the UKs withdrawal from the European Union, NICE’s relationship with EMA and indeed, the para...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read more